PD-1 inhibition is noted as very promising for myeloma, though clinical trials haven’t shown a promising ORR. Why do you think this is?

Chapter 1

In this segment, Dr Lesokhin discusses the potential of checkpoint inhibition for multiple myeloma.

Chapter 2

Can anything be done to mitigate the toxicity of PD-1/PD-L1 inhibition in myeloma?

In this segment, Dr Lesokhin discusses the management of toxicity related to PD-1 blockade in myeloma, including the possibility of re-challenge.

Chapter 3

What potential does CAR-T cell therapy have in myeloma?

In this segment, Dr Lesokhin discusses how CAR-T cell therapy may be used in patients with multiple myeloma.

Chapter 4

What other research is promising, and where do you expect myeloma research to be in 5 years?

In this segment, Dr Lesokhin discusses new and emerging classes of drugs likely to transform treatment for patients with myeloma.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs